Reviewing Aligos Therapeutics (ALGS) and Its Rivals

Aligos Therapeutics (NASDAQ:ALGS) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Aligos Therapeutics to related companies based on the strength of its dividends, valuation, analyst recommendations, earnings, institutional ownership, risk and profitability.

Analyst Recommendations

This is a summary of current recommendations for Aligos Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1	0	5	1	2.86
Aligos Therapeutics Competitors	9834	15121	45433	1587	2.54

Aligos Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 845.95%. As a group, “Biotechnology” companies have a potential upside of 102.42%. Given Aligos Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than its peers.

Volatility and Risk

Aligos Therapeutics has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500. Comparatively, Aligos Therapeutics’ peers have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Profitability

This table compares Aligos Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Aligos Therapeutics Competitors	-12,357.18%	-197.96%	-30.56%

Earnings and Valuation

This table compares Aligos Therapeutics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aligos Therapeutics	$2.19 million	-$24.19 million	-0.56
Aligos Therapeutics Competitors	$719.50 million	$12.16 million	-15.19

Aligos Therapeutics’ peers have higher revenue and earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Aligos Therapeutics beats its peers on 9 of the 13 factors compared.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.